Pancreas Transplant Rejection
Conditions
Brief summary
This pilot study aims to validate the use of vascularised donor-derived sentinel skin flaps for diagnosing rejection in pancreas transplantation. The aim of the study is to investigate the use of sentinel skin flaps in clinical practice and assess whether rejection occurs concordantly or discordantly between the skin flap and the transplanted abdominal organs. If successful, sentinel skin may allow improved immune surveillance and thereby facilitate earlier treatment of rejection with subsequent improvements in allograft survival and patient morbidity.
Interventions
OTHERSentinel skin flap
Donor-derived vascularised composite allograft (sentinel skin flap)
Sponsors
University of Oxford
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Recipient of a pancreas transplant (SPK or PTA) * Participant is willing and able to give informed consent for participation in the study * Male or Female, aged 18 years or above
Exclusion criteria
* Patient does not have a patent ulna artery in either forearm * Recipient of an enterically drained PTA * Patient has received any investigational medical drug within 30 days of transplantation * Patient is not willing to return to Oxford for all clinical follow-up for 12 months * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the trial, or the participant's ability to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concordant allograft rejection | 12 months | If there is any clinical suspicion of rejection then both the sentinel skin flap and visceral allograft will be biopsied. Concordant rejection will be recorded where rejection is confirmed in both the sentinel skin flap and the visceral allograft. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Discordant rejection of the sentinel skin | 12 months | If there is any clinical suspicion of rejection then both the sentinel skin flap and visceral allograft will be biopsied. Discordant rejection will be recorded where there is rejection of the sentinel skin without rejection of the visceral allograft. |
| Discordant rejection of the visceral allograft | 12 months | If there is any clinical suspicion of rejection then both the sentinel skin flap and visceral allograft will be biopsied. Discordant rejection will be recorded where there is rejection of the visceral allograft without rejection of the sentinel skin. |
| Donor specific antibodies | 12 months | Development of de novo donor specific antibodies |
| Immunosuppression | 12 months | Total dose immunosuppression |
| Graft survival | 12 months | Pancreas allograft survival |
Countries
United Kingdom
Contacts
Primary ContactJames CH Barnes
Outcome results
None listed